Your Trusted GLP-1 Resource

Introduction One of the most overlooked side effects of rapid weight loss on GLP-1 medications is muscle loss. When the pounds come off quickly — and on Ozempic, they often do — not all of that weight is fat. Research published in 2025-2026 has shown that 25-40% of weight lost on GLP-1 agonists can come from lean body mass, not just fat. That’s a problem. Muscle isn’t just about looking toned — it’s your metabolic engine. Less muscle means a slower metabolism, which makes it harder to maintain weight loss long-term. It also increases your risk of frailty, falls, and metabolic disease as you age. ...

Introduction Getting the Ozempic dosage right is one of the most important factors in your weight loss journey. Start too fast, and side effects can be unbearable. Go too slow, and you might wonder if the medication is even working. In 2026, with millions of patients now using semaglutide for weight loss, the dosing protocols have been refined based on real-world data from clinical practice — not just clinical trials. ...

Introduction If you’re starting Ozempic (semaglutide) — or considering it — you’ve probably heard about the side effects. And they’re real. But understanding what’s normal, what’s manageable, and what’s a red flag can make the difference between a successful treatment journey and giving up too soon. This guide draws on peer-reviewed clinical trials, FDA adverse event data, and real patient experiences to give you the clearest picture available in 2026. ...

Introduction The two heavyweight champions of GLP-1 weight loss — Ozempic (semaglutide) and Mounjaro (tirzepatide) — dominate the conversation in 2026. But which one should you choose? This comparison is based on head-to-head clinical trials, real-world data, and 2026 pricing and insurance information. We’ll cover effectiveness, side effects, cost, and practical considerations to help you make an informed decision with your doctor. Quick Comparison: At a Glance Feature Ozempic (Semaglutide) Mounjaro (Tirzepatide) Drug Class GLP-1 receptor agonist Dual GIP/GLP-1 receptor agonist Manufacturer Novo Nordisk Eli Lilly FDA Approved For Type 2 diabetes (2017); Weight loss as Wegovy (2021) Type 2 diabetes (2022); Weight loss as Zepbound (2023) Dosing Frequency Once weekly Once weekly Max Dose for Weight Loss 2.4 mg (Wegovy) 15 mg (Zepbound) Average Weight Loss at Max Dose ~15% of body weight ~21-23% of body weight Administration Prefilled pen Single-dose pen (autoinjector) Effectiveness: Mounjaro Wins — But by How Much? The SURMOUNT-1 Trial (Mounjaro/Zepbound) In the landmark SURMOUNT-1 trial, participants on tirzepatide 15 mg lost an average of 20.9% of body weight at 72 weeks (treatment-regimen estimand). The efficacy estimand — which measures results when participants stayed on treatment — showed up to 22.5% weight loss. At the 10 mg dose, average weight loss was 19.5%. PMID: 35658024 ...